Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth

Molecular Pharmacology

Volumn 62, Issue 5, 2002, Pages 1207-1214

  Wick, Marilee ^a   Hurteau, Greg ^a   Dessev, Christina ^a   Chan, Daniel ^a   Geraci, Mark W ^a   Winn, Robert A ^a   Heasley, Lynn E ^a   Nemenoff, Raphael A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; LUCIFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC SULFIDE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; DRUG EFFECT; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN FAMILY; TARGET CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIVISION; CELL LINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036839817     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.5.1207     Document Type: Article

References (40)

1. Brockman JA, Gupta RA, and Dubois RN (1998) Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115:1049-1055.
2. Chang T-H and Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxiseme proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 60:1129-1138.
3. Dannenberg AJ and Zakim D (1999) Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 26:499-504.
4. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, and Glass CK (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol Cell Biol 17:2166-2176.
5. Duperron C and Castonguay A (1997) Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18:1001-1006.
6. Forman BM, Chen J, and Evans RM (1996) The peroxisome proliferator-activated receptors: Ligands and activators. Ann NY Acad Sci 804:266-275.
7. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812.
8. Giaccone G (1996). Oncogenes and antioncogenes in lung tumorigenesis. Chest 109(5 Suppl):130S-134S.
9. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, et al. (2000) A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759.
10. He TC, Chan TA, Vogelstein B, and Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345.
11. 2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 272:14501-14504.
12. 16. J Biol Chem 271:349-354.
13. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, and Moody TW (1998) Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res 18:775-782.
14. Huang Y, He Q, Hillman MJ, Rong R, and Sheikh MS (2001) Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61:6918-6924.
15. Hubbard WC, Alley MC, Gray GN, Green KC, McLemore TL and Boyd MR (1989) Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 49:826-832.
16. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, and Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559.
17. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819.
18. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, et al. (1999) Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 162:331-340.
19. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997) Peroxisome proliferater-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410.
20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
21. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, and Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569.
22. Marks F, Furstenberger G, and Muller-Decker K (1999) Metabolic targets of cancer chemoprevention: Interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res 151:45-67.
23. Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589.
24. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, and Gazdar AF (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353-1362.
25. Nikitakis NG, Hamburger AW, and Sauk JJ (2002) The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res 62:1004-1007.
26. Ohta T, Elnemr A, Yamamote M, Ninomiya I, Fushida S, Nishimura GI, Fujimura T, Kitagawa H, Kayahara M, Shimizu K, et al. (2002) Thiazolidinediene, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 21:37-42.
27. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809.
28. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, and Tarnawski AS (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293.
29. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, and Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18:6013-6020.
30. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, and Reddy BS (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55:1464-1472.
31. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, and Ahnen DJ (2001) Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res 61:1541-1547.
32. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, and Evans RM (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4:1058-1061.
33. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, and Eng C (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3:799-804.
34. Schreinemachers DM and Everson RB (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5:138-146.
35. Smith WL, Meade EA, and DeWitt DL (1994) Interactions of PGH synthase isozymes-1 and -2 with NSAIDS. Ann NY Acad Sci 744:50-57.
36. Spiegelman BM (1997) Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 2:457-464.
37. Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, and Taketo MM (2000) Suppression of intestinal polyposis in ApcDelta 716 knockout mice by an additional mutation in the cytosolic phospholipase A2 gene. J Biol Chem 275:34013-34016.
38. Tegeder I, Pfeilschifter J, and Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072.
39. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada T, Kohno M, Inoue K, Hla T, and Kondo M (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405.
40. Van Putten V, Refaat Z, Dessev C, Blaine S, Wick M, Butterfield L, Han SY, Heasley LE, and Nemenoff RA (2001) Induction of cytosolic phospholipase A2 by oncogenic Ras is mediated through the JNK and ERK pathways in rat epithelial cells. J Biol Chem 276:1226-1232.